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ESSAY

“REVERSE” PATENT DECLARATORY JUDGMENT ACTIONS:
A PROPOSED SOLUTION FOR MEDTRONIC

M EGAN M. LA BELLE†
INTRODUCTION
The United States Supreme Court has taken an interest in shaping patent
law in recent years, deciding many important cases, a number of which have
involved special procedural rules created by the Federal Circuit.1 With the
† Associate Professor, Catholic University of America Columbus School of Law. The author
would like to thank Michael Burstein, Will Hubbard, Paul Gugliuzza, and David Orlic for their
extremely helpful comments. The author is also grateful to her research assistant, Daniel Kane,
and the editors of the University of Pennsylvania Law Review for their excellent research and
editorial assistance.
1 See, e.g., Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2111, 2114
(2013) (holding that a naturally occurring, isolated DNA segment is not patentable subject matter),
aﬀ’g in part, rev’g in part 689 F.3d 1303 (Fed. Cir. 2012); Gunn v. Minton, 133 S. Ct. 1059, 1063-64,
1068 (2013) (rejecting the Federal Circuit’s rule that patent malpractice claims are within the
exclusive jurisdiction of the federal courts), declining to follow Immunocept, LLC v. Fulbright &
Jaworski, LLP, 504 F.3d 1281 (Fed. Cir. 2007); Microsoft Corp. v. i4i Ltd. P’ship, 131 S. Ct. 2238,
2242-43 (2011) (aﬃrming the Federal Circuit’s rule that patent invalidity must be proven by clear
and convincing evidence), aﬀ’g 598 F.3d 831 (Fed. Cir. 2010); Bilski v. Kappos, 130 S. Ct. 3218,
3226-27 (2010) (aﬃrming the Federal Circuit’s ruling, but rejecting its endorsement of the
“machine-or-transformation” test as the sole test of subject matter eligibility), aﬀ’g 545 F.3d 943
(Fed. Cir. ����); KSR Int’l Co. v. Teleﬂex Inc., ��� U.S. ���, ���, ���-22 (2007) (promoting an
expansive obviousness standard and holding that the Federal Circuit’s “teaching, suggestion, or
motivation” test should be ﬂexibly applied), rev’g 119 F. App’x 282 (Fed. Cir. 2005); MedImmune,
Inc. v. Genentech, Inc., 549 U.S. 118, 132 n.11 (2007) (rejecting the Federal Circuit’s “reasonable
apprehension of suit” test for determining the justiciability of declaratory judgment actions), rev’g
427 F.3d 958 (Fed. Cir. 2005); eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388, 390 (2006)
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Court scheduled to hear Medtronic Inc. v. Boston Scientiﬁc Corp. in early
November, this term is no exception.2 The issue in Medtronic is whether the
burden of proof in patent declaratory judgment actions (DJ actions) should
be on the patent owner (i.e., the defendant) to prove infringement or on the
accused infringer (i.e., the plaintiﬀ) to prove noninfringement.3 Ordinarily,
the patent owner bears the burden of proving infringement, and the declaratory posture of a suit does not shift that burden.4 In Medtronic, however,
the Federal Circuit created an exception for “MedImmune-type” cases—that
is, declaratory judgment actions where the plaintiﬀ is a licensee in good
standing—since the patent owner cannot counterclaim for infringement.5
“Because the declaratory judgment plaintiﬀ is the only party seeking the aid
of the court,” the Federal Circuit reasoned, it should bear the burden of
proving noninfringement.6
Medtronic and its supporting amici (including the United States) argue
that the Supreme Court should reverse the opinion below because the
Federal Circuit misallocated the burden of proof as a legal matter and
because the Federal Circuit’s rule undermines the policy goal of encouraging patent validity challenges.7 Without disputing Medtronic’s position,
this short Essay suggests, ﬁrst, that Medtronic sweeps more broadly than the
parties have acknowledged, and, second, that there may be an additional—
and perhaps simpler—ground for reversing the Federal Circuit.
The litigants all appear to believe that the Federal Circuit’s new exception is limited to MedImmune-type suits, but Medtronic could be interpreted
more expansively. In Medtronic, the Federal Circuit shifted the burden of proof
to the accused infringer because the patent owner could not counterclaim for
(holding that the traditional four-factor test for permanent injunctions applies to patent cases),
vacating 401 F.3d 1323 (Fed. Cir. 2005).
2 See 133 S. Ct. 2393 (2013) (granting certiorari); Medtronic, Inc. v. Boston Scientiﬁc Corp.,
SCOTUSBLOG, http://www.scotusblog.com/case-files/cases/medtronic-inc-v-boston-scientific-corp
(last visited Oct. 7, 2013). The Court has also agreed to review two cases concerning the patent
fee-shifting statute, 35 U.S.C. § 285 (2006). See Octane Fitness, LLC v. ICON Health & Fitness,
Inc., No. 12-1184, 2013 WL 1283843, at *1 (Oct. 1, 2013), granting cert. to 496 F. App’x 57 (Fed. Cir.
2012); Highmark, Inc. v. Allcare Health Mgmt. Sys., Inc., No. 12-1163, 2013 WL 1217353, at *1
(Oct. 1, 2013), granting cert. to 687 F.3d 1300 (Fed. Cir. 2012).
3 See Brief for Petitioner at i, Medtronic, 133 S. Ct. 2393 (No. 12-1128), 2013 WL 3935883.
4 See Medtronic Inc. v. Bos. Scientific Corp., 695 F.3d 1266, 1272 (Fed. Cir. 2012), cert. granted,
133 S. Ct. 2393 (2013).
5 Id. at 1273-74. In MedImmune-type suits, plaintiﬀs generally seek a declaration that the
patent is invalid and/or that certain products are not covered by the terms of the license so that
they no longer have to pay royalties.
6 Id. at 1274.
7 See, e.g., Brief for Petitioner, supra note 3, at 38-47; Brief for the United States as Amicus
Curiae Supporting Petitioner at 24-31, Medtronic, 133 S. Ct. 2393 (No. 12-1128), 2013 WL 3990879.
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infringement. Yet, there are declaratory judgment actions outside the
MedImmune context where an infringement counterclaim is also precluded.
For instance, plaintiﬀs sometimes ﬁle “anticipatory” declaratory judgment
actions before engaging in any potentially infringing activities.8 In these
suits, the patent owner cannot counterclaim for infringement because no
infringing activity has occurred. Under the logic of Medtronic, therefore, the
burden of proof would shift to the plaintiﬀ in this category of cases even
though there’s no license involved.
Whether limited to MedImmune-type suits or not, the Federal Circuit’s
reasoning in Medtronic is signiﬁcantly ﬂawed. While it’s true that patent
owners cannot counterclaim for infringement in certain types of declaratory
judgment actions, they may always counterclaim for a declaration of future
infringement.9 In other words, the patent owner in Medtronic was not, as the
Federal Circuit determined, precluded from “seeking the aid of the court”;10
instead, the owner could have asked the court to resolve the infringement
question by ﬁling a “reverse” declaratory judgment action against the accused
infringer. Thus, the Federal Circuit’s rationale for crafting this exception was
wholly unjustiﬁed, and Medtronic should be reversed.
I. T HE D ECLARATORY JUDGMENT A CT
The Declaratory Judgment Act (DJ Act), which was enacted in 1934,11
provides that “[i]n a case of actual controversy within its jurisdiction, . . .
any court of the United States, upon the ﬁling of an appropriate pleading,
may declare the rights and other legal relations of any interested party
seeking such declaration.”12 The DJ Act further provides that “[a]ny such

8 See, e.g., Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 689 F.3d 1303 (Fed. Cir.
2012), rev’d in part on other grounds, 133 S. Ct. 2107 (2013). In Myriad, the Federal Circuit held that
one of the plaintiﬀs, Dr. Ostrer, demonstrated an actual case or controversy even though he had
not yet engaged in any infringing activity because Ostrer “not only has the resources and expertise
to immediately undertake clinical BRCA testing, but also states unequivocally that he will
immediately begin such testing.” Id. at 1320-21.
9 See Lang v. Pac. Marine & Supply Co., 895 F.2d 761, 764 (Fed. Cir. 1990) (holding that a
patentee may seek a declaration of infringement against a future infringer as long as the case-orcontroversy requirement, U.S. C ONST. art. III, § �, cl. �, is satisﬁed). Medtronic cites Lang once
in its brief, Brief for Petitioner, supra note 3, at 39, yet neither the parties nor the amici focus on
the argument that the patent owner could have counterclaimed for a declaration of future
infringement.
10 See Medtronic, 695 F.3d at 1273-74.
11 Ch. ���, �� Stat. ��� (����) (codiﬁed as amended at �� U.S.C. § 2201 (2006)).
12 28 U.S.C. § 2201(a).
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declaration shall have the force and eﬀect of a ﬁnal judgment or decree and
shall be reviewable as such.”13
The Supreme Court has held that the DJ Act “enlarge[s] the range of remedies available in the federal courts but d[oes] not extend their jurisdiction.”14
Like many remedial devices, the DJ Act is transsubstantive, meaning it is
available in all federal civil suits regardless of the substantive nature of the
underlying claims.15 From the outset, though, the DJ Act has played a
prominent role in patent cases. Indeed, the legislative history demonstrates
that Congress speciﬁcally considered patent rights while debating the DJ Act:
I assert that I have a right to use a certain patent. You claim that you have a
patent. What am I going to do about it? There is no way I can litigate my
right, which I claim, to use that device, except by going ahead and using it,
and you can sit back as long as you please and let me run up just as high a
bill of damages as you wish to have me run up, and then you may sue me
for the damages, and I am ruined, having acted all the time in good faith
and on my best judgment, but having no way in the world to ﬁnd out
whether I had a right to use that device or not.16

Thus, Congress enacted the DJ Act, at least in part, to provide accused
infringers with a procedural remedy to counter the use of patents as “scarecrows” to quash competition.17
Over the past eighty years, the DJ Act has been invoked in a number of
patent cases—usually by accused infringers who have been threatened by
patent owners. Yet for more than two decades now, it has been well settled that
patent owners also have the right to seek declaratory relief, as long as a justiciable controversy exists.18 Despite this precedent, reverse declaratory judgment

13
14
15

Id.
Skelly Oil Co. v. Phillips Petroleum Co., 339 U.S. 667, 671 (1950).
See H.R. REP. NO. 70-366, at 2 (1928) (noting that a declaratory judgment “may be
applied to the ascertainment of almost any determinative fact or law”).
16 Declaratory Judgments: Hearings on H.R. 5623 Before a Subcomm. of the S. Comm. on the Judiciary, 70th Cong. 35 (1928) (statement of E.R. Sunderland).
17 See Cardinal Chem. Co. v. Morton Int’l, Inc., 508 U.S. 83, 95-96 (1993) (quoting Judge
Learned Hand’s opinion in Bresnick v. U.S. Vitamin Corp., 139 F.2d 239, 242 (2d Cir. 1943)).
18 See, e.g., Lang v. Pac. Marine & Supply Co., 895 F.2d 761, 764 (Fed. Cir. 1990) (“If the
controversy requirement is met by a suﬃcient allegation of immediacy and reality, we see no
reason why a patentee should be unable to seek a declaration of infringement against a future
infringer when a future infringer is able to maintain a declaratory judgment action for noninfringement under the same circumstances.”); see also Metabolite Labs., Inc. v. Lab. Corp. of Am.
Holdings, 370 F.3d 1354, 1369 (Fed. Cir. 2004) (“Although not as common as the scenario in
which the alleged infringer seeks declaratory judgment against the patentee, it is possible for a
patentee to also seek a declaratory judgment against a future infringer.” (citation omitted));
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actions have been rare—perhaps because of the diﬃculty patent owners faced
in proving a justiciable controversy. Thanks to the Supreme Court’s decision
in MedImmune, Inc. v. Genentech, Inc.,19 however, that justiciability hurdle is
now easier to overcome.
II. M EDIMMUNE V. G ENENTECH
As with all suits brought in federal court, plaintiﬀs seeking declaratory
judgments must demonstrate that there is an actual case or controversy for
the court to resolve.20 This can prove diﬃcult since declaratory relief is an
anticipatory remedy that addresses future conduct. Because justiciability is
often challenged in patent declaratory judgment actions, the Federal Circuit
has fashioned tests for determining when a case or controversy exists in
both “standard” and “reverse” DJ actions.
With respect to standard DJ actions, the accused infringer must prove
that, (1) based on the defendant’s conduct, it had a reasonable apprehension
of suit at the time it ﬁled the action; and, (2) it produced, or made meaningful preparations to produce, an allegedly infringing product.21 For reverse
DJ suits, the Federal Circuit established in Lang that patent owners must
show that, (1) the accused infringer was engaged in an activity directed
toward making, selling, or using a patented product that would subject it to
an infringement charge, or was making meaningful preparation for such an
activity; and, (2) the acts of the accused infringer indicate a refusal to
change the course of its actions despite acts by the patent owner suﬃcient
to create a reasonable apprehension of suit.22
For years, these tests posed signiﬁcant hurdles for patent litigants seeking
declaratory relief. The issue came to a head in MedImmune—a standard DJ
action—where the Supreme Court addressed whether an accused infringer,
who was also a licensee, could sue for declaratory relief.23 The Federal
Circuit had decided that, because the license protected the licensee from an
infringement suit, there was no “reasonable apprehension of suit” and thus
no case or controversy.24 The Supreme Court reversed and held that a licensee
in good standing may sue for declaratory relief as long as “the facts alleged,
Lawrence M. Sung, Intellectual Property Protection or Protectionism? Declaratory Judgment Use by
Patent Owners Against Prospective Infringers, 42 A M. U. L. R EV. 239 (1992).
19 549 U.S. 118 (2007).
20 See U.S. C ONST . art. III, § 2, cl. 1.
21 See Shell Oil Co. v. Amoco Corp., 970 F.2d 885, 887 n.2 (Fed. Cir. 1992).
22 895 F.2d at 764.
23 See 549 U.S. at 120-21.
24 MedImmune, Inc. v. Genentech, Inc., 427 F.3d 958, 962-65 (Fed. Cir.), rev’d, 549 U.S.
118 (2005).
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under all the circumstances, show that there is a substantial controversy,
between parties having adverse legal interests, of suﬃcient immediacy and
reality to warrant the issuance of a declaratory judgment.”25
In reaching this decision, the Supreme Court found the Federal Circuit’s “reasonable apprehension of suit” test to be in conﬂict with Court
precedent.26 Instead, whether plaintiﬀs in a patent declaratory judgment
action have established a justiciable controversy depends on the totality of
the circumstances—just like in any other declaratory judgment suit.27 In
other words, there is no special justiciability test for patent cases.
Since MedImmune, the Federal Circuit has been all over the map with
respect to the justiciability of patent declaratory judgment actions.28 What’s
clear, though, is that MedImmune made it easier to prove an actual case or
controversy between the parties. And while the Federal Circuit has yet to
address MedImmune’s impact on reverse declaratory judgment actions, every
district court to address the question agrees that MedImmune’s more lenient
standard is equally applicable when a patent owner—rather than an accused
infringer—is the party seeking declaratory relief.
III. REVERSE D ECLARATORY JUDGMENT A CTIONS
POST-M EDIMMUNE
Before MedImmune, the Federal Circuit had adopted unique tests for
evaluating the case-or-controversy requirement in both standard and reverse
patent declaratory judgment actions. In the immediate wake of MedImmune,
the Federal Circuit acknowledged that it would have to alter its approach to
justiciability in standard DJ actions.29 Because reverse suits are relatively
rare, however, the Federal Circuit has not had the chance to consider them
post-MedImmune. In the meantime, a few district courts have weighed in on
the question and have uniformly held that MedImmune applies with equal
force to reverse patent declaratory judgment suits.
25 MedImmune, 549 U.S. at 127, 137 (quoting Md. Cas. Co. v. Pac. Coal & Oil Co., 312 U.S.
270, 273 (1941)).
26 Id. at 132 n.11 (citing Altvater v. Freeman, 319 U.S. 359 (1943); Md. Cas. Co., 312 U.S. at
273; and Aetna Life Ins. Co. v. Haworth, 300 U.S. 227, 239 (1937)).
27 Id. at 127.
28 See Megan M. La Belle, Patent Law as Public Law, 20 G EO . M ASON L. R EV . 41, 77-79
(2012) (collecting cases).
29 See, e.g., SanDisk Corp. v. STMicroelectronics, Inc., 480 F.3d 1372, 1380-81 (Fed. Cir.
2007) (“The Supreme Court’s opinion in MedImmune represents a rejection of our reasonable
apprehension of suit test. . . . We need not deﬁne the outer boundaries of declaratory judgment
jurisdiction, which will depend on the application of the principles of declaratory judgment
jurisdiction to the facts and circumstances of each case.”).
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In Eisai Co. v. Mutual Pharmaceutical Co., for example, the patent owner
brought a reverse DJ action seeking a declaration of future infringement,
and the defendant (i.e., the accused infringer) moved to dismiss on justiciability grounds.30 To resolve the motion, the district court ﬁrst had to
determine the standard for evaluating justiciability in reverse declaratory
judgment actions: did the Federal Circuit’s Lang test apply or was MedImmune now controlling? Citing similarities between the Lang test and the
recently invalidated test for standard DJ actions, the district court held that
MedImmune applies to reverse patent declaratory judgment actions.31
Accordingly, patent owners seeking declaratory relief for future infringements must demonstrate a case or controversy under MedImmune’s totality
of the circumstances standard.32
Other district courts have reached the same conclusion as the Eisai
court, but through slightly diﬀerent reasoning. Cordance Corp. v. Amazon.com, Inc.33 is a good example. There, Cordance sued Amazon for
infringement, and Amazon counterclaimed for a declaration of future
infringement of one of its patents.34 In moving to dismiss Amazon’s
counterclaim, Cordance argued that MedImmune was distinguishable
because it dealt with a standard DJ action, while Amazon’s counterclaim
should continue to be governed by Lang.35 The U.S. District Court for the
District of Delaware disagreed, reiterating MedImmune’s holding that the
totality of the circumstances standard should apply to all types of suits
brought under the Declaratory Judgment Act, including reverse DJ cases.36
The court then concluded that Amazon had established a case or controversy
under MedImmune and denied Cordance’s motion to dismiss.37
At bottom, it seems clear that MedImmune’s more ﬂexible standard applies
to reverse patent declaratory judgment actions. To be sure, it is unlikely
that the Supreme Court would reject a special justiciability test for standard
DJ actions, but uphold a similar test for reverse suits. Accordingly, as long
30
31

No. 06-3613, 2007 WL 4556958, at *14 (D.N.J. Dec. 20, 2007).
See id. at *16 (“[B]ecause the Federal Circuit equated the second Lang prong with the nowrejected reasonable apprehension of suit in a ‘normal’ declaratory judgment action, the second
Lang prong is no longer good law.”).
32 Id.; see also Geisha, LLC v. Tuccillo, 525 F. Supp. 2d 1002, 1004, 1012-13 (N.D. Ill. 2007)
(concluding that MedImmune applies in reverse declaratory judgment actions involving trademark
infringement).
33 521 F. Supp. 2d 340 (D. Del. 2007).
34 Id. at 341-42.
35 Id. at 343 n.13.
36 Id. at 344 n.13, 345.
37 Id. at 345-46.
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as the totality of the circumstances creates an actual case or controversy,
patent owners may seek declarations of future infringement against licensees just as licensees may seek declarations of future noninfringement
against patent owners.
IV. M EDTRONIC V. BOSTON SCIENTIFIC
Because the background of Medtronic is somewhat complicated, this Part
provides a brief summary of those facts essential to this Essay. Medtronic and
defendants Boston Scientiﬁc Corporation and Guidant Corporation are all
leading manufacturers of medical devices. In 1991, Medtronic agreed to license
U.S. Patent No. 4,928,688 (the ‘688 patent) from Eli Lilly & Co., Guidant’s
predecessor-in-interest to the patent.38 Sometime thereafter, the U.S. Patent
and Trademark Oﬃce reissued the ‘688 patent as United States Reissued
Patent Nos. RE 38,119 and RE 39,897 (collectively “the reissue patents”).39
In December ����, Medtronic ﬁled a declaratory judgment action in the
U.S. District Court for the District of Delaware against Boston Scientiﬁc,
Guidant, and Mirowski Family Ventures LLC (MFV) (collectively “defendants”) seeking a declaration of noninfringement and invalidity as to the
reissue patents.40 Defendants did not contest justiciability, perhaps because
the parties had previously entered into a “Litigation Tolling Agreement”
that speciﬁcally recognized that “an actual controversy exists . . . as to the
scope, validity and enforceability of the [reissue patents].”41 Of course, the
case-or-controversy requirement is a true jurisdictional limitation that
cannot be waived by the parties,42 so the district court could have—but did
not—raise justiciability on its own.
The case proceeded to a bench trial where the judge had to decide,
among other things, which party should bear the burden of proof as to
infringement. Defendants argued that Medtronic, as plaintiﬀ, should have
the burden of proving noninfringement, while Medtronic took the position
that defendants, as patent owners, always bear the burden of proving
infringement.43 The trial court agreed with Medtronic, citing Federal
38 Medtronic Inc. v. Bos. Scientific Corp., 777 F. Supp. 2d 750, 758, 761 (D. Del. 2011),
vacated, 695 F.3d 1266 (Fed. Cir. 2012), cert. granted, 133 S. Ct. 2393 (2013).
39 Id.
40 Id. at 757-58. MFV, the assignee of the reissue patents, exclusively licensed them to Guidant, a wholly owned subsidiary of Boston Scientiﬁc. Id. at 758.
41 Id. at 759 (citations and internal quotation marks omitted).
42 See, e.g., Lea Brilmayer, The Jurisprudence of Article III: Perspectives on the “Case or Controversy”
Requirement, 93 H ARV. L. R EV. 297, 298 (1979) (stating that if there is no case or controversy,
“courts are without power to proceed, regardless of the wishes of the parties”).
43 Medtronic, 777 F. Supp. 2d at 765.
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Circuit cases holding that “[t]he burden is always on the patentee to show
infringement”44 and never shifts to the accused infringer.45 Applying this
standard, the court then concluded that defendants failed to meet their burden
and issued a declaratory judgment of noninfringement in favor of Medtronic.46
On appeal, defendants persuaded the Federal Circuit that the trial court
had misallocated the burden of proof on infringement. The Federal Circuit
acknowledged that in ordinary patent declaratory judgment actions, the
patent owner counterclaims for infringement and thus bears the burden of
proof.47 In MedImmune-type cases, however, “the continued existence of the
license precludes the very infringement counterclaim that normally would
impose the burden of proving infringement on the patentee.”48 Therefore,
the Federal Circuit reasoned, in this limited circumstance where the patent
owner cannot counterclaim and the accused infringer is the only party who
may “seek[] the aid of the court,” the burden of persuasion lies with the
licensee to show noninfringement of the patents in suit.49 Given the district
court’s misallocation of the burden of proof, the Federal Circuit vacated the
judgment below and remanded for further proceedings on the question of
infringement.50
Medtronic ﬁled a petition for certiorari, which the Supreme Court
granted in May.51 Medtronic has now ﬁled its opening brief, and oral
argument is scheduled for November 5, 2013.52 Two amicus briefs have been
ﬁled in support of Medtronic, one of them by the United States.53 Petitioner
and its amici argue that the Federal Circuit’s new rule regarding the burden
of proof is not only legally erroneous but also problematic from a policy
perspective because it deters patent validity challenges.54 The purpose of
this Essay is certainly not to challenge these arguments, but instead to focus
on an alternative ground for reversing the decision below.

44 Id. (alteration in original) (quoting Under Sea Indus., Inc. v. Dacor Corp., 833 F.2d 1551,
1557 (Fed. Cir. 1987)).
45 Id. at 765-66 (citing several Federal Circuit decisions).
46 Id. at 782-83.
47 See Medtronic Inc. v. Bos. Scientiﬁc Corp., ��� F.�d ����, ���� (Fed. Cir. ����) (noting
that such counterclaims are compulsory), cert. granted, 133 S. Ct. 2393 (2013).
48 Id. at 1273.
49 Id. at 1274.
50 See id. at 1274-75 (noting that it would be within the district court’s discretion to allow
Medtronic to amend its interrogatory answer to include additional noninfringement contentions).
51 Medtronic Inc. v. Bos. Scientiﬁc Corp., ��� S. Ct. ���� (����).
52 See SCOTUS BLOG , supra note 2.
53 See id.; see also Brief for the United States as Amicus Curiae Supporting Petitioner, supra
note 7.
54 See supra note 7 and accompanying text.
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V. T HE FEDERAL C IRCUIT W RONGLY C ONCLUDED THAT
D EFENDANTS C OULD N OT FILE A C OUNTERCLAIM
In Medtronic, the Federal Circuit held that accused infringers should
bear the burden of proof in declaratory judgment actions when the patent
owner is precluded from ﬁling a counterclaim for infringement.55 The
problem with this decision, aside from the legal and policy considerations
raised by Medtronic and its amici, is two-fold. First, the Federal Circuit
claims that this exception is limited to MedImmune-type suits, but its
reasoning sweeps far more broadly. Under Medtronic, the burden of proof
will shift in any DJ action in which the patent owner cannot counterclaim
for infringement. This is not limited to suits between licensees and licensors,
but includes any anticipatory declaratory relief action where the accused
infringer has not yet engaged in infringing conduct.56 This possibility of
Medtronic extending beyond the MedImmune context raises very real concerns
about the far-reaching implications of the Federal Circuit’s decision.
Second, and perhaps more fundamentally, the Medtronic decision is
based on a faulty premise. The fact that a license is in place or that a
plaintiﬀ has not yet infringed does not preclude counterclaims in DJ
actions. Instead, it means only that patent owners will have to ﬁle a diﬀerent type of counterclaim—one that focuses on future infringement.57 As one
district court recently explained, “The Federal Circuit has held that the
proper vehicle for a suit to redress the future infringement would be an
action under the Declaratory Judgment Act . . . rather than a suit under 35
U.S.C. § 271 alone.”58
Thus, contrary to the Federal Circuit’s holding in Medtronic, the defendants’ hands were not tied by the license.59 Just as Medtronic was able to sue
for declaratory relief notwithstanding the license, the defendants could have
counterclaimed with a DJ suit of their own. Indeed, the Federal Circuit
55
56

695 F.3d at 1274.
See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 689 F.3d 1303, 1319-21 (Fed.
Cir. 2012) (allowing one plaintiﬀ ’s declaratory judgment action to proceed even though he had not
yet engaged in infringing activity), rev’d in part on other grounds, 133 S. Ct. 2107 (2013); Telectronics
Pacing Sys., Inc. v. Ventritex, Inc., 982 F.2d 1520, 1526-27 (Fed. Cir. 1992) (acknowledging that a
patent owner may seek declaration of future infringement, but dismissing the patent owner’s claim
in the instant case for failure to demonstrate an actual case or controversy).
57 See supra Parts I, III. Notably, the Medtronic defendants did initially ﬁle a counterclaim for
declaratory relief, but it concerned the right to recover money paid into an escrow account—not
future infringement. 695 F.3d at 1273 n.2. That counterclaim was dismissed without prejudice
pursuant to a joint stipulation of the parties. Id.
58 WesternGeco L.L.C. v. Ion Geophysical Corp., 776 F. Supp. 2d 342, 351 (S.D. Tex. 2011)
(citing Lang v. Pac. Marine & Supply Co., 895 F.2d 761, 765 (Fed. Cir. 1990)).
59 See supra notes 9-10 and accompanying text.
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recognized this explicitly in Lang, holding that, as long as there’s a justiciable
controversy, a patentee’s right to seek a declaration of infringement against
a future infringer mirrors the right of a future infringer to seek a declaration
of noninfringement against a patentee.60
There’s little doubt that the defendants in Medtronic could have demonstrated the requisite case or controversy. For starters, the parties speciﬁcally
recognized that “an actual controversy exists . . . as to the scope, validity
and enforceability of the [reissue patents].”61 There was also a long history
of litigation among the parties concerning the patents in suit,62 which
suggests a justiciable controversy.63 More to the point, however, Medtronic’s
ﬁling of a declaratory judgment action unquestionably created the case or
controversy necessary for defendants to counterclaim for declaratory
relief.64 In fact, there’s a good argument that a counterclaim for a declaration of future infringement is not merely permissive under these circumstances but actually compulsory,65 just as infringement counterclaims are
compulsory in response to DJ actions brought by nonlicensees.66
In the end, the Federal Circuit should not have shifted the burden of
proof to the accused infringer in Medtronic simply because the patent owner
was precluded from asserting a counterclaim for present infringement. The
patent owner had another option—it could have (and perhaps should have)
sought a declaration of future infringement. The fact that the patent owner,
for whatever reason, chose not to ﬁle such a counterclaim should have no
impact on the burden of proof.67 Thus, the Supreme Court should reject the
60
61

See 895 F.2d at 764.
Medtronic Inc. v. Bos. Scientiﬁc Corp., ��� F. Supp. �d ���, ��� (D. Del. ����), vacated,
695 F.3d 1266 (Fed. Cir. 2012), cert. granted, 133 S. Ct. 2393 (2013) (citations and internal
quotation marks omitted).
62 Id. at 758.
63 See, e.g., Prasco, LLC v. Medicis Pharm. Corp., 537 F.3d 1329, 1341 (Fed. Cir. 2008) (“Prior
litigious conduct is one circumstance to be considered in assessing whether the totality of
circumstances creates an actual controversy.”).
64 See, e.g., Arteris S.A.S. v. Sonics, Inc., No. 12-0434, 2013 WL 3052903, at *5 (N.D. Cal.
June 17, 2013) (“[B]ecause Arteris’ patent claims were pending at the time Sonics ﬁled its noninfringement and invalidity counterclaims, a case or controversy existed when the counterclaims
were ﬁled.”).
65 See FED. R. CIV. P. 13(a)(1) (requiring a party to plead as a counterclaim any claim that “arises
out of the transaction or occurrence that is the subject matter of the opposing party’s claim”).
66 Medtronic, 695 F.3d at 1272 (Fed. Cir. 2012) (citations omitted).
67 It appears that defendants did not assert such a counterclaim in Medtronic under the misapprehension that a licensor receiving royalty payments is ineligible to seek the aid of the court.
See Brief for Respondent Mirowski Family Ventures at 27, Medtronic, 133 S. Ct. 2393 (No. 121128), 2013 WL 5172001. Of course, had they raised a counterclaim for future infringement, they
would not have been able to advance the burden-shifting argument that ultimately prevailed at the
circuit level. Thus, allowing the allocation of the burden of proof to depend on whether the patent
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exception created by Medtronic and hold that the same rules regarding
burden of proof apply in all patent declaratory judgment actions.
C ONCLUSION
Medtronic is the latest example of the Federal Circuit’s creation of special procedural rules for patent cases, a trend that the Supreme Court has
consistently eschewed in recent years.68 It is well established that patent
owners bear the burden of proof on infringement and that the declaratory
posture of the suit does not alter that burden. That a patent owner may be
unable to counterclaim for present infringement in certain situations does
not justify an exception to these rules. MedImmune held that all declaratory
judgment actions should be treated equally, and Medtronic will now provide
the Supreme Court with the opportunity to remind the Federal Circuit of
this guiding principle.
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owner asserts a counterclaim invites exactly the kind of gamesmanship the Declaratory Judgment Act
was intended to eliminate. See supra Part I (discussing Congress’s reasons for enacting the DJ Act).
68 See Sarah Tran, Policy Tailors and the Patent Oﬃce, 46 U.C. D AVIS L. R EV . 487, 492 n.17
(2012) (cataloguing a series of recent cases in which the Court has rejected these rules).

